Ovarian tissue cryopreservation is considered as a useful option to preserve fertility for cancer patients. This study purposed to evaluate the change of telomere length and senescence markers during human ovarian tissue cryopreservation. Ovarian tissues were obtained from women who underwent benign ovarian surgery in the gynecology research unit of a university hospital with prior consent and IRB approval. DNA was extracted from the ovarian tissues using a DNeasy tissue kit and telomere lengths in the DNA samples were determined by real time PCR before and after cryopreservation. All tissues were stained with hematoxylin-eosin and subjected to immunohistochemistry and TUNEL assays. Other senescence markers, including p53, p16, p21, and phospho-pRb proteins, were evaluated using western blot analysis. Ovarian tissues were collected from ten patients and prepared for slow freezing with the same size of diameter 4 mm and 1 mm thickness. Mean age of patients was 26.7 ± 6.2 years (range, 16-34 years), and ovarian tissues were cryopreserved and thawed 4 weeks after cryopreservation. The mean telomere length was significantly decreased after cryopreservation (9.57 ± 1.47 bp vs. 8.34 ± 1.83 bp, p = 0.001). Western blot analysis revealed that p53, p16, and p21 proteins increased and phospho-pRb protein expression decreased after ovarian tissue cryopreservation. Ovarian tissue cryopreservation and transplantation is regarded as one of promising options for fertility preservation. However, clinicians and researchers should be aware of possible irreversible DNA changes such as shortening of telomere length and alterations of other senescence markers in human ovarian tissues.
PMID 33500500 33500500 DOI 10.1038/s41598-021-81973-3 10.1038/s41598-021-81973-3 Kim et al. 2021, Kim 2021
Cite this article
Kim, B., Ryu, K. J., Lee, S., & Kim, T. (2021). Changes in telomere length and senescence markers during human ovarian tissue cryopreservation. Scientific reports. https://doi.org/10.1038/s41598-021-81973-3
Kim B, Ryu KJ, Lee S, Kim T. Changes in telomere length and senescence markers during human ovarian tissue cryopreservation. Scientific reports. 2021. doi:10.1038/s41598-021-81973-3
Kim, B., et al. "Changes in telomere length and senescence markers during human ovarian tissue cryopreservation." Scientific reports, 2021.
Related articles
Cancer and Fertility · Fertility Preservation Before Treatment
Blumenfeld Z, 2012·Best practice & research. Clinical obstetrics & gynaecology
The overall increase in cancer prevalence and the significant increase in long-term survival have generated worldwide interest in preserving fertility in young women exposed to gonadotoxic chemo- and radiotherapy. Infertility represents one of the main long-term consequences of combination chemotherapy given for lymphoma, leukaemia and other malignancies in young women. The gonadotoxic effect of various chemotherapeutic agents is diverse, may involve a variety of pathophysiologic mechanisms, and is not unequivocally understood. Proliferating cells, such as in tissues with high turnover (i.e. bone marrow, gastrointestinal tract and growing ovarian follicles) are more vulnerable to the toxic effect of alkylating agents. These agents may also be cytotoxic to cells at rest, as they are not cell-cycle specific. Alkylating agents, the most gonadotoxic chemotherapeutic medications, cause dose-dependent, direct destruction of oocytes and follicular depletion, and may bring about cortical fibrosis and ovarian blood-vessel damage. The reported rate of premature ovarian failure after various diseases and chemotherapeutic protocols differ enormously, and depend mainly on the chemotherapeutic protocol used and age range of the woman. Several options have been proposed for preserving female fertility, despite gonadotoxic chemotherapy: ovarian transposition, cryopreservation of embryos, unfertilised metaphase-II oocytes and ovarian tissue, and administration of gonadotropin-releasing hormone agonistic analogs in an attempt to decrease the gonadotoxic effects of chemotherapy by simulating a prepubertal hormonal milieu. None of these methods is ideal and none guarantees future fertility in all survivors; therefore, a combination of methods is recommended for maximising women's chances of future fertility.
Cancer and Fertility · Fertility Preservation Before Treatment
This systematic review and meta-analysis examined the relationship between menstrual cycle phases and the incidence of muscle injuries in female team sport athletes, following PRISMA 2020 and PERSiST guidelines. A comprehensive search was conducted in PubMed, Scopus, and SPORTDiscus from inception to mid-January 2024. Studies were included if they examined female team sport athletes of reproductive age with regular menstrual cycles and compared the occurrence of muscle injuries across at least two menstrual phases. Studies involving hormonal contraceptive use, medications affecting the menstrual cycle or musculoskeletal system, or menstrual dysfunction were excluded. Three studies met the inclusion criteria, involving 318 participants. Meta-analysis yielded a pooled Risk Ratio of 1.18 (95% CI: 0.75 to 1.86, p = 0.46) for injury risk between the luteal and follicular phases, suggesting no statistically significant association. However, the certainty of the cumulative evidence was rated as very low due to methodological limitations, including inconsistent phase classifications and reliance on imprecise methods for identifying menstrual phases. Consequently, no practical or clinical recommendations can be made at this time. Future research employing standardised, physiologically accurate methods for classifying and detecting menstrual cycle phases is necessary to better understand the potential links between hormonal fluctuations and injury risk. Supplementary Information: The online version contains supplementary material available at 10.1038/s41598-026-36763-0.
Iodine, an essential trace element, may play a role in reproductive health through its extrathyroidal actions. This study aimed to investigate the effects of iodine supplementation on oocyte apoptosis and proliferation in women with diminished ovarian reserve. A quasi-experimental study was conducted on ten women undergoing two cycles of ovarian stimulation. In the first cycle, they followed the standard protocol, while in the second, they received a daily 150 µg iodine supplement for two months. Urinary iodine levels, cumulus cell apoptosis and necrosis, and PCNA expression were evaluated before and after supplementation. We found that iodine supplementation significantly improved women's iodine status, increasing it from borderline sufficiency to optimal levels. This improvement was accompanied by a significant increase in the number of metaphase II oocytes. Following iodine supplementation, we observed a marked increase in cumulus cell viability and a reduction in both early and late apoptosis. Additionally, the expression of PCNA was upregulated, showing a positive association with the percentage of live cells and a reduction in total apoptosis. These findings suggest that iodine supplementation could be a promising therapeutic strategy for improving oocyte quality and enhancing fertility outcomes, particularly in women with diminished ovarian reserve.